Obesity

Health Megan Molteni

In the era of GLP-1 drugs, demand for bariatric surgery plunges

Pharmalot Lizzy Lawrence, Elaine Chen, and Ed Silverman

STAT Plus: Eli Lilly weight loss drug shortage underscores deeper issues with FDA oversight

Biotech Elaine Chen

STAT Plus: Ozempic linked to lower risk of Alzheimer’s diagnosis in observational study

Health Tara Bannow

More state Medicaid programs consider covering GLP-1 drugs

Biotech Elaine Chen

STAT Plus: Novo asks FDA to bar compounders from making Ozempic copies

Health Elizabeth Cooney

Dietary guidelines panel stresses fruits and vegetables but stops shy of major changes 

Health Elizabeth Cooney

Dietary experts advise skipping guidelines on ultra-processed foods — for now

Biotech Elizabeth Cooney

STAT Plus: Amgen, Biogen and Takeda talk about R&D on tough targets

Pharmalot Ed Silverman

STAT Plus: Consumer and labor groups urge FTC to block Catalent sale to Novo Holdings

The Readout LOUD Elaine Chen, Adam Feuerstein, and Allison DeAngelis

Biotech’s next gold rush, GLP-1 shortages, and STAT Summit highlights

D.C. Diagnosis Rachel Cohrs Zhang

DC Diagnosis: Bristol Myers CEO Chris Boerner on drug price negotiation and the election

Morning Rounds Theresa Gaffney

Morning Rounds: How UnitedHealth pressured doctors on diagnoses

Health Elizabeth Cooney

STAT Plus: Q&A: FDA chief on why our hearts are less healthy, how obesity drugs impress him, and what worries him

Morning Rounds Theresa Gaffney

Morning Rounds: Why aren’t we doing better on cardiovascular health?

Special Report Elizabeth Cooney

11 experts on why gains in cardiovascular disease are stalling and what we can do about it

Special Report Elizabeth Cooney

Heart disease experts in their own words: ‘This is solvable and this is preventable’

Pharma Katie Palmer

STAT Plus: In stark reversal, FDA to reconsider removal of Eli Lilly weight loss drug from shortage list

Health Elaine Chen

STAT Plus: As Eli Lilly, compounders battle over weight loss drugs, patients are caught in the middle

Politics John Wilkerson

STAT Plus: Medicare already covers GLP-1s for half of seniors with obesity, new report finds

Pharmalot Ed Silverman

STAT Plus: Compounding group sues FDA for removing Lilly’s obesity drug from its shortages list

Pharmalot Adam Feuerstein

STAT Plus: Pharmalittle: We’re reading about an Italian acquisition, Medicare Advantage market growth, and more

The Readout LOUD Adam Feuerstein, Allison DeAngelis, and Elaine Chen

STAT Plus: Biden’s health care AI czar, a new obesity company, and its dealmaking CEO

Adam's Take Adam Feuerstein

STAT Plus: Ron Renaud, biotech’s serial CEO, is ready for a new assignment — and maybe another deal?

Biotech Allison DeAngelis

STAT Plus: $400 million for an obesity drug startup? A new venture is a sign of the times

Biotech Elaine Chen

STAT Plus: An obesity startup wastes no time: With drugs in early testing, Metsera lines up manufacturing

Pharma Andrew Joseph

STAT Plus: Roche seeks to project confidence on its obesity drugs — and sees room to make its mark

Morning Rounds Brittany Trang

A big week for rats, genetics of picky eating, and research misconduct rules

Health Isabella Cueto and Theresa Gaffney

Intermittent fasting for teens? Obesity study finds benefits but only under careful supervision

The Readout LOUD Allison DeAngelis, Adam Feuerstein, and Elaine Chen

Cannabinoids for weight loss, a cancelled ad comm, and the Fed lowers interest rates